Global High-Priority Regulatory Events — April 27, 2026

27-04-2026

IDBI Bank Limited announced that a Board of Directors meeting will be held on April 30, 2026, to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2026, in compliance with SEBI (LODR) Regulations. The Trading Window for dealing in the Bank's securities by designated persons and their immediate relatives will remain closed until May 02, 2026, per the Bank's Code of Conduct and SEBI (Prohibition of Insider Trading) Regulations.

• ·Filing reference to Regulations 29 and 50 of SEBI (LODR) Regulations, 2015.
• ·Regd. Office: IDBI Tower, WTC Complex, Cuffe Parade, Mumbai - 400 005.
• ·CIN: L65190MH2004G01148838.

27-04-2026

27-04-2026

Mangalore Refinery and Petrochemicals Limited (MRPL) discloses that the Board of Directors of its holding company ONGC has approved the formation of an Integrated Petrochemicals Marketing & Trading Joint Venture Company with shareholding ratios of 50:25:25 by ONGC, MRPL, and OPaL respectively. MRPL will contribute ₹12.5 Cr towards the equity share capital of the JV, subject to approval from the Department of Investment and Public Asset Management (DIPAM), Ministry of Finance, Govt. of India. The JV aims to integrate petrochemicals marketing of group companies, achieve synergies to reduce costs and increase revenue through improved pricing, logistics, and production of speciality grades, and enable third-party sales.

• ·Shareholding ratio in JV: 50% ONGC, 25% MRPL, 25% OPaL
• ·Approval pending from Department of Investment and Public Asset Management (DIPAM), Ministry of Finance, Govt. of India
• ·Communication received from ONGC on 27/04/2026

27-04-2026

Vikas WSP Ltd., under CIRP since February 2, 2022 and managed by Resolution Professional Darshan Singh Anand, informed that on April 27, 2026, the NCLT Chandigarh Bench heard applications including IA 764/2022 (cooperation from ex-management), IA 1537/2022 (PUFE transactions), IA 1470 (EPFO revised claim), and IA 1870 (Income Tax revised claim), with orders reserved on the latter two. The key application for approval of the Resolution Plan (IA 1538/2022) could not be taken up due to delays. The matters are now listed for further hearing on May 4, 2026.

• ·Scrip Code: 519307
• ·ISIN: INE706A01022
• ·IP Registration No.: IBBI/IPA-002/IPN00326/2017-2018/10931
• ·CIRP commenced: February 2, 2022
• ·RP appointment confirmed by CoC: March 17, 2022

27-04-2026

Tesla, Inc. filed a Form S-8 registration statement on April 24, 2026, to register 303,960,630 shares of its common stock ($0.001 par value) issuable to Elon Musk under the 2018 CEO Performance Award granted on January 21, 2018, following an Implementation Agreement entered on April 21, 2026. The filing incorporates Tesla's 10-K for the fiscal year ended December 31, 2025, filed January 29, 2026, and includes standard provisions on director/officer indemnification. No financial performance metrics, period-over-period comparisons, or monetary amounts are disclosed.

• ·Tesla classified as large accelerated filer.
• ·Award granted January 21, 2018.
• ·Registration covers additional shares from stock dividends, splits, etc., per Rule 416(a).

27-04-2026

Seaport Therapeutics, Inc. is filing an S-1/A for an IPO offering 11,800,000 shares of voting common stock at a midpoint price of $17.00 per share, expecting net proceeds of approximately $183.5 million (or $211.4 million if underwriters' option for 1,770,000 additional shares is exercised in full), plus up to $18.6 million from a concurrent private placement. Proceeds will fund development of lead programs GlyphAlloTM (SPT-300), GlyphAgoTM (SPT-320), and Glyph2BLSDTM (SPT-348). However, the company reported widening net losses of $74.9 million for 2025 versus $46.9 million in 2024, driven by R&D expenses surging 164% to $66.3 million, despite G&A expenses declining 23% to $21.0 million.

• ·1-for-3.1407 reverse stock split effective April 24, 2026.
• ·8,798,389 shares issuable upon exercise of outstanding stock options as of Dec 31, 2025 (weighted-average exercise price $4.68).
• ·2,182,978 shares to be granted to an executive officer and director post-IPO to maintain 12.5% ownership on fully diluted basis.
• ·Proposed Nasdaq symbol: SPTX.
• ·Directed share program reserves up to 5% of shares for directors, officers, employees.

27-04-2026

Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire all outstanding shares of Organon & Co. for $14.00 per share in cash, implying an enterprise value of $11.75 billion. The transaction positions the combined entity among the top 25 global pharmaceutical companies with $12.4 billion in revenue, strengthens Sun Pharma's women's health and biosimilars portfolios, and is expected to nearly double EBITDA and cash flow, though post-transaction Net Debt/EBITDA stands at 2.3x. The deal awaits regulatory approvals and Organon stockholder approval, with closure anticipated in early 2027 amid risks such as potential delays, competing bids, or failure to consummate.

• ·Transaction to be funded by Sun Pharma's cash resources and bank financing.
• ·Organon portfolio includes over 70 products commercialized in 140 countries.
• ·Combined company presence in 150 countries, with 18 large markets each over $100M revenue.
• ·Advisors: J.P. Morgan and Jefferies (Sun Pharma financial), Morgan Stanley and Goldman Sachs (Organon financial).

27-04-2026

Ultra Clean Holdings, Inc. (UCTT) has filed its DEF 14A Proxy Statement for the 2026 Annual Meeting of Stockholders on May 22, 2026, at 12:30 p.m. PT, held virtually only. Key proposals include electing directors, ratifying PricewaterhouseCoopers LLP as independent auditors for fiscal 2026, an advisory vote on named executive officer compensation, and approvals of amendments and restatements to the stock incentive plan and employee stock purchase plan. The record date is March 27, 2026, with 44,825,713 shares of common stock outstanding.

• ·Annual meeting is virtual only at www.virtualshareholdermeeting.com/UCTT2026; physical attendance not permitted.
• ·Proxy materials available at http://materials.proxyvote.com.
• ·Board recommends voting FOR all proposals.

27-04-2026

RYTHM, Inc. filed a DEF 14A proxy statement for its virtual Annual Meeting of Stockholders on June 16, 2026, at 3:00 p.m. Central Time, proposing the election of seven directors (Benjamin Kovler, Max Holtzman, Timothy Mahoney, Peter Shapiro, Sanjay Tolia, Armon Vakili, and Krishnan Varier), ratification of GuzmanGray as independent auditor for the fiscal year ending December 31, 2026, and approval of an amendment to the 2022 Omnibus Equity Incentive Plan to increase available Common Stock by 115,000 shares. As of the record date of April 20, 2026, 2,149,128 shares of Common Stock were outstanding. No financial performance metrics or period-over-period comparisons are provided in the filing.

• ·Virtual meeting access: www.virtualshareholdermeeting.com/RYM2026
• ·Record date: April 20, 2026
• ·Proxy materials mailed on or about April 29, 2026
• ·Post-meeting reception at Garcia’s Chicago (1001 W Washington Blvd, Chicago, IL 60607) starting at 3:30 p.m. Central Time

27-04-2026

Velo3D, Inc. has issued a proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on June 10, 2026, seeking approval to elect two Class II directors (Stefan Krause and new nominee Lily Mei), ratify Frank, Rimerman + Co. LLP as independent auditors for the year ending December 31, 2026, approve advisory votes on named executive officer compensation and say-on-pay frequency (recommending every 1 year), and amend the 2021 Equity Incentive Plan by increasing authorized common shares by 2,860,000. The record date is April 15, 2026. No financial performance metrics or period-over-period comparisons are discussed.

• ·Annual Meeting held virtually at www.virtualshareholdermeeting.com/VLD2026.
• ·Record Date: April 15, 2026.
• ·Filing Date: April 27, 2026.
• ·Board majority independent (3 out of 5 directors); all committees composed of independent directors.

27-04-2026

Irenic Acquisition Corp., a Cayman Islands-incorporated blank check company, filed Amendment No. 2 to its S-1 registration statement on April 27, 2026, solely to include exhibits ahead of its proposed IPO. Estimated offering expenses total $1,000,000, excluding underwriting discounts, with sponsor Irenic Sponsor, LLC holding 6,325,000 founder shares (adjustable to maintain 20% ownership post-offering) after initial issuance for $25,000 and prior surrender. Sponsor and underwriters committed to purchasing 640,000 private placement units at $10.00 each ($6,400,000 total), increasing to 706,000 ($7,060,000) if over-allotment exercised.

• ·Founder shares represent 20% of outstanding shares post-offering (excluding private placement shares and underlying warrants).
• ·Sponsor accredited investor; securities issued under Section 4(a)(2) exemption.
• ·No underwriting discounts paid on sponsor/private placement sales.
• ·Offering expected to commence as soon as practicable post-effectiveness.

27-04-2026

SkyWater Technology, Inc. (SKYT) has issued a proxy statement for its 2026 Annual Meeting of Stockholders, scheduled virtually on June 10, 2026, at 9:00 a.m. ET, to elect nine director nominees and ratify KPMG LLP as independent auditors for fiscal 2026. The meeting may not occur if the pending merger with IonQ, Inc., announced January 25, 2026, closes prior, as disclosed in a separate merger proxy filed March 31, 2026. Record date is April 13, 2026, with 49,157,448 shares of common stock outstanding.

• ·Annual Meeting held virtually only at www.virtualshareholdermeeting.com/SKYT2026; physical attendance not permitted.
• ·Fiscal year ends on the Sunday closest to the end of the twelfth calendar month; fiscal 2025 ended December 28, 2025.
• ·Board consists of nine directors, all standing for election annually.

27-04-2026

MetaVia Inc. (MTVA) has issued a proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on June 8, 2026, at 10:00 a.m. ET, seeking approval for electing two Class I directors for three-year terms, ratifying BDO USA, P.C. as independent auditors for FY 2026, a discretionary reverse stock split of 1-for-5 to 1-for-22, amending the 2022 Equity Incentive Plan to add 200,000 shares, and authorizing adjournments for Proposals 3 and 4 if needed. As of the April 13, 2026 record date, 5,164,370 shares of Common Stock (par value $0.001) were outstanding, with a quorum requiring one-third of voting power present. The Board unanimously recommends voting FOR all proposals; no financial performance metrics or period comparisons are discussed.

• ·Virtual meeting access: www.virtualshareholdermeeting.com/MTVA2026; requires 16-digit control number to vote remotely.
• ·Proxy voting deadline: 11:59 p.m. ET on June 7, 2026 via Internet.
• ·Proposal 1 (director election): plurality vote; Proposals 2, 4, 5: majority of voting power present; Proposal 3: majority of votes cast.
• ·Broker non-votes have no effect on any proposals; only Proposal 2 is routine (broker discretionary).

27-04-2026

Green Thumb Industries Inc. (GTBIF) filed its DEF 14A proxy statement dated April 27, 2026, for the virtual annual and special shareholder meeting on June 16, 2026, at 2:00 p.m. CT, covering proposals to set the board at seven directors, elect directors, advisory approval of named executive officer compensation, re-appoint Baker Tilly US, LLP as auditors, and amend articles to modify automatic conversion of Super Voting Shares. The record date is April 20, 2026; no specific financial metrics or period-over-period comparisons are detailed in the provided filing excerpt, which focuses on governance and voting logistics.

• ·Voting deadline: 10:59 p.m. CT on June 12, 2026, or 48 hours before any adjournment.
• ·Post-meeting reception at Garcia’s Chicago (1001 W Washington Blvd, Chicago, IL 60607) at 3:30 p.m. CT on June 16, 2026.
• ·Proxy materials available at investors.gtigrows.com/2026proxy and 2026 Annual Report (including 10-K for year ended December 31, 2025) at investors.gtigrows.com/2026annualreport.

27-04-2026

On April 22, 2026, GAMCO Natural Resources, Gold & Income Trust (NYSE: GNT) entered into a Sales Agreement with G.research, LLC to offer and sell up to 1,000,000 common shares of beneficial interest at-the-market, with a minimum price not less than the current net asset value per share plus commission. The offering commenced on April 24, 2026, pursuant to a prospectus supplement dated April 24, 2026, and an accompanying prospectus dated February 5, 2024, under effective shelf registration statement Form N-2 (File No. 333-276020). No shares have been sold yet, and the agreement enables flexible capital raising without specified financial impact.

• ·Common shares par value $0.001 per share
• ·Securities registered on New York Stock Exchange under symbols GNT and GNT Pr A
• ·Registration Statement File No. 333-276020

27-04-2026

Alternus Clean Energy reported zero revenues for both the three months ($0 vs $93 thousand) and nine months ($0 vs $280 thousand) ended September 30, 2025, a 100% YoY decline, with ongoing operating losses of $984 thousand in Q3. However, the nine-month net loss from continuing operations improved 64% to $4,694 thousand from $13,067 thousand, aided by a $15,513 thousand gain on sale of subsidiaries, while total assets expanded over 644% to $57,510 thousand driven by a business combination adding $37,980 thousand in intangibles and $18,964 thousand goodwill, flipping shareholders' equity to a positive $22,626 thousand. Cash and equivalents dwindled to $39 thousand from $161 thousand at year-end 2024 amid operating cash use of $2,321 thousand.

• ·Customer relationships intangible: $26,190 thousand (24-year life)
• ·Favorable contracts intangible: $10,930 thousand (15-year life)
• ·Operating cash flow used: $2,321 thousand for nine months ended Sep 30, 2025 (vs $1,820 thousand prior)
• ·Pro forma net loss nine months Sep 30, 2025: $6,263 thousand

27-04-2026

Ladder Capital Corp reported net income attributable to Class A common shareholders of $2,605 thousand for the three months ended March 31, 2026, down 78% YoY from $11,775 thousand amid higher costs and expenses ($48,739 thousand, up 20% YoY) and lower other income ($28,863 thousand vs. $30,874 thousand). However, net interest income rose 13% YoY to $23,017 thousand, total assets expanded 9% QoQ to $5,606,678 thousand, supported by growth in mortgage loan receivables to $2,606,374 thousand. Total equity dipped slightly to $1,444,535 thousand.

• ·Basic EPS $0.02 for Q1 2026 vs. $0.09 for Q1 2025
• ·Dividends declared $29,347 thousand in Q1 2026
• ·Net cash used in operating activities $7,989 thousand in Q1 2026 (improved from $28,727 thousand used in Q1 2025)
• ·Mortgage loan receivables held for investment $2,606,374 thousand as of March 31, 2026 (up from $2,217,375 thousand at Dec 31, 2025)

27-04-2026

TOP Ships Inc. filed a preliminary Form F-1 registration statement on April 24, 2026, for the public offering of up to 3,690,036 Units, each consisting of one common share or one pre-funded warrant to purchase one common share and one-and-a-half Class D warrants to purchase common shares, underwritten by Maxim Group LLC as sole placement agent. The offering includes up to 3,690,036 common shares underlying pre-funded warrants, 5,535,054 common shares underlying Class D warrants, and 184,501 common shares underlying placement agent warrants. Recently, on February 18, 2026, the company acquired shares of entities (Tanker SPVs) from related party Central Mare, affiliated with Evangelos J. Pistiolis, holding shipbuilding contracts dated February 3, 2026, for nine 47,499 dwt MR chemical/product oil tankers, with $14.0 million of the purchase price settled via issuance of 14,000 Series G Preferred Shares on March 31, 2026.

• ·Filing incorporates prior SEC filings including Form 6-K on April 24, 2026, and Form 20-F on April 1, 2026.
• ·Indemnification provisions under Marshall Islands Business Corporation Act Section 60 and company bylaws.
• ·Exhibits include multiple amendments to Articles of Incorporation from 2011 to 2022, various warrant forms, employment agreements, and management agreements.

27-04-2026

Zomedica Corp.'s DEF 14A proxy statement discloses governance details, including Audit Committee meetings (4 times), Compensation Committee (3 times), and Nominating Committee (3 times) in 2025, with independent members overseeing key functions. Executive compensation for 2025 showed increases for CEO Larry Heaton (total $762,883 from $647,985 in 2024, +17.7%) and COO Tony Blair (total $390,151 from $367,782 in 2024, +6.1%), while other NEOs like Kevin Klass ($433,398 total) and Mike Zuehlke ($354,387 total) had single-year disclosures with no prior comparisons provided. The filing also profiles current executives and confirms policies like Code of Ethics, Clawback, and separated CEO/Chairman roles.

• ·Board separates Chairman (Mr. Rowe) and CEO (Larry Heaton) roles for balanced oversight.
• ·Audit Committee oversees financial reporting, internal controls, and pre-approves related-person transactions.
• ·Compensation Committee reviews executive comp policies, equity plans, and director compensation.
• ·Nominating Committee uses informal process for director candidates, considers shareholder recommendations.

27-04-2026

Driven Brands Holdings Inc.'s indirect wholly-owned subsidiaries, Driven Holdings Parent LLC and Driven Holdings, LLC, entered into a Fourth Amendment and limited waiver to their revolving credit facility under the Credit Agreement on April 24, 2026. The amendment waives any potential defaults from the intent to restate financial statements for fiscal years ending December 30, 2023, December 28, 2024, and the first three quarters of the fiscal year ending December 27, 2025, while extending the delivery deadline for FY2025 financials to June 10, 2026, and Q1 2026 financials to 45 days thereafter. This signals ongoing financial reporting challenges with no positive operational metrics disclosed.

• ·Fiscal quarters to restate: first three quarters of fiscal year ending December 27, 2025.
• ·Q1 2026 fiscal quarter ends March 28, 2026.
• ·Credit Agreement originally dated May 27, 2021.

27-04-2026

Quantum Leap Acquisition Corp, a Cayman Islands blank check company (SPAC), filed Amendment No. 2 to its S-1 registration statement (No. 333-293359) on April 24, 2026, for an IPO of 20,000,000 units at an undisclosed price, each comprising one Class A ordinary share and one warrant exercisable at $11.50 per share. The offering anticipates 594,500 private placement units sold simultaneously to the sponsor, resulting in 20,594,500 units and 20,594,500 warrants outstanding post-offering, with 6,325,000 Class B founder shares outstanding prior (targeting 25% sponsor ownership post-IPO, subject to forfeiture of up to 825,000 shares if over-allotment not exercised). No operational financials or period comparisons are provided, as the company has no prior assets beyond a $25,000 sponsor investment.

• ·Separate trading of Class A shares and warrants prohibited until Form 8-K filed with audited balance sheet post-closing.
• ·Warrants exercisable 30 days after initial business combination, expire 5 years thereafter; cashless exercise possible under certain conditions.
• ·Founder shares identical to Class A except voting rights pre-combination, transfer restrictions, registration rights, and anti-dilution conversion.
• ·Up to 23,000,000 units if full over-allotment exercised; sponsor ownership maintained at 25% via adjustments.
• ·No redemption rights waived by sponsor/officers/directors for founder/private shares in business combination.

27-04-2026

Cintas Corporation (CTAS) entered into a merger agreement on March 10, 2026, to acquire UniFirst Corporation (UNF) through a two-step merger process, with UniFirst shareholders receiving $155.00 in cash and 0.7720 shares of Cintas common stock per UniFirst share. Cintas expects to issue approximately 14,261,683 shares, resulting in UniFirst shareholders owning 3.4% of the combined company post-merger, while current Cintas shareholders retain 96.6%. The UniFirst board unanimously recommends approval, supported by a voting agreement from the Croatti family controlling approximately two-thirds of UniFirst's voting power; a special shareholder meeting is scheduled for [•], 2026.

• ·UniFirst common stock trades on NYSE under symbol 'UNF'; Cintas common stock trades on NASDAQ under 'CTAS'.
• ·UniFirst special meeting to be held virtually on [•], 2026, at 10:00 a.m. ET; record date [•], 2026.
• ·Merger requires two-thirds approval of combined voting power of UniFirst shares; no appraisal rights for shareholders.
• ·UniFirst will delist from NYSE and deregister under Exchange Act post-merger.

27-04-2026

Everforth, Inc. (f/k/a ASGN Incorporated) has issued its 2026 Proxy Statement for the Annual Meeting on June 11, 2026, seeking stockholder approval for the election of three incumbent directors—Mark A. Frantz, Carol J. Lindstrom, and Arshad Matin—for three-year terms expiring in 2029, an advisory vote on named executive officer compensation for the year ended December 31, 2025, and ratification of Deloitte & Touche LLP as independent auditors for the year ending December 31, 2026. The Board size will decrease from 10 to 9 directors effective upon the retirement of Mr. Holman at the meeting's conclusion. The record date for voting eligibility is April 16, 2026.

• ·Annual Meeting location: The St. Regis San Francisco, 125 Third Street, San Francisco, CA 94103 at 9:00 a.m. Pacific Time.
• ·Board diversity: Three women directors, one Hispanic-American, one Asian-American.
• ·Voting methods: Telephone (1-800-652-VOTE), internet (www.investorvote.com/Everforth), mail, or in person.

27-04-2026

On April 20, 2026, Suncrete, Inc. increased its Board of Directors from seven to nine members, appointing Charles Owens as a Class I director (term expiring 2027) and Noreen Skelly as a Class II director (term expiring 2028), both joining the Audit Committee with Skelly as Chair. Owens brings extensive construction industry experience as a founder and former CEO of Construction Partners, Inc. (ROAD), while Skelly offers deep financial expertise as CFO of Blue Sky Bank and former CFO roles at multiple banks. The Board also granted restricted stock awards totaling 528,000 shares (96,000 Class A, 432,000 Class B) to eight non-employee directors under the 2026 Omnibus Incentive Plan as board service compensation.

• ·Restricted stock vests two-thirds on second anniversary and one-third on third anniversary of April 20, 2026 grant date, subject to continued service.
• ·New directors determined independent under SEC and Nasdaq rules; no arrangements or material interests under Item 404(a) of Regulation S-K.
• ·Director Grants issued under Section 4(a)(2) and/or Regulation D exemption from Securities Act registration.

27-04-2026

Oppenheimer Holdings Inc. (OPY) agreed to a $70 million settlement of the 'Cash Sweep' class action litigation filed in June 2025, avoiding a jury trial where plaintiffs sought over $440 million in damages based on discovery assertions. The settlement, subject to District Court approval within up to 90 days and formal documentation within 60 days, provides a full release of claims without admission of liability and is fully tax-deductible, but will significantly impact Q1 2026 earnings despite competitive rates during the disputed period from 2022. Class certification was granted on December 8, 2025, with trial set for June 2026.

• ·Litigation: Liberty Capital Group v. Oppenheimer Holdings Inc., et al., No. 1:25-cv04822-JSR, U.S. District Court Southern District of New York
• ·Company headquartered in New York with institutional businesses in London, Tel Aviv, and Hong Kong
• ·Earnings release expected May 1, 2026; Form 10-Q for quarter ended March 31, 2026 filed around same time

27-04-2026

SiteOne Landscape Supply, through its subsidiaries SiteOne Landscape Supply Holding, LLC and SiteOne Landscape Supply, LLC, entered into the First Amendment to the Amended and Restated Credit Agreement dated July 22, 2022, on April 22, 2026. The amendment facilitates the exit of certain Exiting Lenders, entry of New Lenders, reallocation of commitments among Existing and New Lenders, and prepayment of existing loans with new revolving credit loans upon the First Amendment Effective Date. No specific changes to commitment amounts or financial terms are detailed in the filing, with schedules amended but not quantified here.

• ·Original Credit Agreement dated July 22, 2022
• ·Fee Letter dated March 9, 2026
• ·Effectiveness subject to execution by Lenders representing 100% of Commitments, guarantor consents, certificates, representations and warranties, no Default, legal opinion, and payment of fees/expenses

27-04-2026

Nature Wood Group Ltd reported revenue of $14,584 thousand for the year ended December 31, 2025, a 10.7% YoY decline from $16,341 thousand in 2024, amid sharp drops in Europe and China while Asia grew. Gross profit fell 74.2% YoY to $1,400 thousand with margin contracting to 9.6% from 33.3%, driven by losses in logs (-6.3% margin) and decking (-0.5% margin), though flooring improved to 23.3% margin. Net loss narrowed to $5,856 thousand from $8,729 thousand, aided by a $561 thousand profit from discontinued operations, but cash balances declined to $967 thousand.

• ·Cash used in operating activities: $907 thousand in 2025 vs generated $2,319 thousand in 2024.
• ·Administrative expenses increased to $3,416 thousand in 2025 from $2,381 thousand in 2024.
• ·Revenue by geography: China $6,503,329 (down from $7,650,663), Asia $5,531,033 (up from $4,056,712).
• ·Impairment loss on financial asset: $3,003 thousand in 2025.

27-04-2026

Orchid Island Capital, Inc., a REIT investing in Agency RMBS, filed its DEF 14A proxy statement for the 2026 Annual Meeting to elect six directors (four independent, one-third women), ratify BDO USA, P.C. as independent auditors for the fiscal year ending December 31, 2026, approve executive compensation on a non-binding basis, and recommend 'every one year' frequency for future say-on-pay votes. The Board held 17 meetings in 2025 with robust governance practices including stock ownership guidelines, prohibitions on pledging/hedging, insider trading policy, and compensation clawback. Record date for voting is April 9, 2026.

• ·Annual election of all directors under majority voting standard with resignation policy for those not receiving majority votes.
• ·Stockholders of record as of April 9, 2026 entitled to vote; each share has one vote.
• ·Corporate governance includes no poison pill, stockholder power to amend bylaws, and annual review of manager performance.

27-04-2026

Picard Medical, Inc. (PMI) filed an S-1 registration statement on April 27, 2026, in preparation for an initial public offering, including financial statements for the years ended December 31, 2025 and 2024, with revenue segments for Products and Rentals. The filing discloses risks related to customer, product, and geographic concentrations (primarily US, Europe, other foreign countries including RS and CA), ongoing convertible notes (2023, 2024, 2025), senior secured notes, warrants, a reverse stock split effective July 1-11, 2025, and equity incentive plans. No specific financial performance metrics such as revenue growth or declines are quantified in the provided excerpt, limiting period-over-period analysis.

• ·Reverse stock split occurred from July 1 to July 11, 2025.
• ·Company incorporated on April 8, 2021.
• ·Tuscon, AZ lease disclosed for facilities.
• ·Conversions of Series A1 Preferred Stock, convertible notes, and aggregated notes into common stock occurred in July-September 2025 ahead of IPO.
• ·Customer concentrations: Customer A, B, I for sales; A, B, F, H for receivables in 2025.

27-04-2026

CooTek (Cayman) Inc. reported consolidated revenues of $21,712,720 for the year ended December 31, 2025, down 28.4% YoY from $30,318,816 in 2024, driven by lower third-party revenues across subsidiaries and variable interest entities. The company recorded a net loss of $78,179, swinging from a $63,569 profit in 2024, with total cost of revenues and operating expenses at $21,751,509 nearly matching revenues. Total assets declined to $6,855,823 from $8,985,043, and cash and equivalents fell to $3,492,812 from $4,119,090.

• ·Net cash used in operating activities: $77,289 for FY 2025.
• ·Short-term bank borrowings: $2,062,941 as of Dec 31, 2025 (up from none explicitly at parent level in 2024).
• ·Significant risk: Revenues heavily reliant on advertising, with potential for customer loss or reduced spending.
• ·Third-party revenues FY2025: $20,667,394 from Other Company Subsidiaries (down from $27,520,332 in FY2024).

27-04-2026

Ocean Capital Acquisition Corp, a blank check company (SPAC), filed an amended S-1 registration statement on April 27, 2026, detailing its proposed initial public offering. The filing presents multiple pro forma net tangible book value scenarios as of December 31, 2025, accounting for over-allotment option exercise or non-exercise and redemption levels from 0% to 100% of maximum, including pre-offering net tangible book deficits. Private placement units are planned with the Sponsor and SB Capital Holding Corp.

• ·Pro forma calculations as of 2025-12-31 for period 2025-01-01 to 2025-12-31
• ·Scenarios cover no redemption, redemptions at 25%, 50%, 75%, and 100% of maximum
• ·Includes components such as deferred underwriting commissions, offering costs accrued, and ordinary shares outstanding prior to offering

27-04-2026

Fortrea Holdings Inc. (FTRE) filed a DEF 14A proxy statement for its virtual Annual Meeting on June 9, 2026, seeking stockholder approval to elect Anshul Thakral, Peter M. Neupert, and William J. Sharbaugh as Class III directors until the 2028 Annual Meeting, ratify Deloitte & Touche LLP as independent auditors for FY 2026, and conduct an advisory 'Say-on-Pay' vote on named executive officer compensation. As of the April 15, 2026 record date, 94,584,730 shares of common stock were outstanding. The company, a spin-off from Labcorp effective June 30, 2023, employs approximately 14,300 people across 100 countries providing clinical development services.

• ·Annual Meeting time: 8:00 a.m. Eastern Time, virtual at www.virtualshareholdermeeting.com/FTRE2026
• ·Proxy materials and 2025 Annual Report available at www.proxyvote.com as of April 27, 2026
• ·Compensation disclosures reference PEOs including Thomas Pike (2023-2024), Anshul Thakral and Peter Neupert (2025), with Appendix A on non-GAAP metrics

27-04-2026

Domino's Pizza Inc reported total revenues of $1,150,594 thousand for the fiscal quarter ended March 22, 2026, up 3.5% YoY from $1,112,056 thousand, with supply chain revenues increasing 4.4% to $698,973 thousand and international franchise royalties rising 7.2% to $80,980 thousand. However, U.S. company-owned store revenues declined 10.4% to $82,098 thousand, contributing to a 6.6% drop in net income to $139,811 thousand from $149,651 thousand, and diluted EPS fell to $4.13 from $4.33. Operating income grew 9.7% to $230,357 thousand, aided by a $7,780 thousand gain on asset sales, while segment adjusted income from operations increased 4.4% overall to $267,387 thousand.

• ·Operating cash flow declined to $161,955 thousand from $179,076 thousand YoY.
• ·Cash and cash equivalents increased to $232,922 thousand as of March 22, 2026 from $125,675 thousand at December 28, 2025.
• ·Common stock repurchases amounted to $75,098 thousand in Q1 FY26, up from $50,000 thousand in Q1 FY25.
• ·Investment in DPC Dash decreased to $30,080 thousand from $36,070 thousand.

27-04-2026

American Bitcoin Corp. (ABTC) has issued a proxy statement for its 2026 Annual Meeting of Stockholders on June 22, 2026, seeking approval to elect Asher Genoot as Class I director for a three-year term, ratify KPMG LLP as independent auditors for the fiscal year ending December 31, 2026, and authorize a reverse stock split of common stock at a board-determined ratio between 1-for-5 and 1-for-40. The record date is April 23, 2026, with 1,060,449,416 shares of common stock outstanding, including 328,224,513 Class A shares (1 vote each) and 732,224,903 Class B shares (10,000 votes each). No financial performance metrics or period comparisons are disclosed in the filing.

• ·Annual Meeting held virtually at www.virtualshareholdermeeting.com/ABTC2026
• ·Voting rights: Class A common stock (1 vote per share), Class B common stock (10,000 votes per share), Class C common stock (10 votes per share)
• ·Company formed via Hut 8 contribution on March 31, 2025, and Gryphon merger on September 3, 2025
• ·Proxy materials available at www.proxyvote.com

27-04-2026

Commercial Vehicle Group, Inc. (CVGI) filed its DEF 14A Proxy Statement on April 27, 2026, for the virtual Annual Meeting of Stockholders on May 14, 2026, seeking election of seven director nominees, approval of the Second Amended and Restated 2020 Equity Incentive Plan, an advisory vote to approve named executive officer compensation, and ratification of KPMG LLP as independent auditor for the fiscal year ending December 31, 2026. The statement includes executive compensation disclosures referencing Principal Executive Officers (PEOs) James R. Ray (2023-2025), Robert R. Griffin, and Harold Bevis (2021-2022). Record date is March 16, 2026.

• ·Virtual Annual Meeting: May 14, 2026, at 1:00 p.m. Eastern Time via www.virtualshareholdermeeting.com/CVGI2026 (16-digit control number required)
• ·Record Date: March 16, 2026
• ·Fiscal year references: 2025 (Jan 1 - Dec 31, 2025), 2024, 2023, 2022, 2021

27-04-2026

HUYA Inc. reported consolidated third-party revenues of RMB 6,502,400 thousand for the year ended December 31, 2025, up 7.0% YoY from RMB 6,079,115 thousand in 2024, while revenues were down 13.1% in 2024 from RMB 6,994,328 thousand in 2023. However, net loss widened significantly to RMB 112,591 thousand in 2025 from RMB 47,955 thousand in 2024, after improving from RMB 204,519 thousand in 2023. Total assets as of December 31, 2025 stood at RMB 6,701,372 thousand, with shareholders' equity at RMB 4,919,716 thousand.

• ·Hypothetical net distribution to Parent/Shareholders after taxes: 67.50%.
• ·Service fees between subsidiaries and VIE are tax neutral on consolidated basis.
• ·Preferential 15% tax rate for certain subsidiaries and VIE is temporary and subject to qualification.
• ·Withholding tax on dividends could be reduced to 5% under tax treaties (e.g., Hong Kong).
• ·Consolidated loss before income tax: RMB 97,090 thousand in 2025 vs RMB 34,455 thousand in 2024.

27-04-2026

HawkEye 360, Inc., a signals intelligence provider founded in 2015, is filing Amendment No. 1 to its S-1 registration statement for an initial public offering of 16,000,000 shares of common stock priced between $24.00 and $26.00 per share, with listing on the NYSE under 'HAWK'. The company recently completed the acquisition of Innovative Signal Analysis, Inc. in December 2025 and operates over 30 satellites, but as a future public benefit corporation, it will balance stockholder interests with public benefits, potentially not maximizing shareholder value. Underwriters have a 30-day option for an additional 2,400,000 shares.

• ·Founded in 2015 by military veterans, engineers, and national security technologists.
• ·Headquartered at 450 Springpark Place, Suite 500, Herndon, Virginia 20170.
• ·Emerging growth company electing public benefit corporation status upon IPO completion.
• ·Lead underwriters: Goldman Sachs & Co. LLC, Morgan Stanley.
• ·Registration No. 333-294965, filed April 27, 2026.

27-04-2026

Fulcrum Therapeutics reported positive Phase 1b PIONEER trial data for pociredir showing robust HbF induction, hemolysis/anemia improvements, and VOC reduction trends, with plans to initiate a potential registration-enabling trial in H2 2026 and cash of $333.3M supporting runway into 2029. However, Q1 2026 net loss widened 7% YoY to $18.9M, driven by R&D expenses up 5% to $14.1M and G&A up 16% to $8.1M, while cash decreased $19.0M QoQ to $333.3M. The company appointed Josh Lehrer to its Board and announced CFO Alan Musso's retirement later in 2026.

• ·Dosed first patient in open-label long-term dosing trial for pociredir.
• ·PIONEER trial abstract accepted for oral presentation at Foundation for Sickle Cell Disease Research Symposium in June 2026.
• ·Working capital of $328.8M as of March 31, 2026, down from $344.4M as of December 31, 2025.
• ·Pociredir granted Fast Track and Orphan Drug Designation from FDA for SCD.

27-04-2026

Auddia Inc. commenced a public offering on April 24, 2026, issuing 1,405,006 shares of common stock, pre-funded warrants to purchase 3,679,737 shares, and common warrants to purchase 5,084,743 shares at $2.36 per unit (or $2.359 per pre-funded unit), expected to generate approximately $12 million in gross proceeds and $10.9 million in net proceeds after fees. The net proceeds will fund working capital and general corporate purposes, with Dawson James Securities, Inc. as placement agent receiving a 7.0% cash fee and a 90-day lock-up on new share issuances imposed. Common warrants expire upon the pending merger with McCarthy Finney, Inc. (announced February 17, 2026) or five years from exercise.

• ·Pre-funded warrants immediately exercisable with $0.001 exercise price.
• ·Common warrants immediately exercisable at $2.36, adjustable downward by board, expire on merger closing or 5 years from initial exercise.
• ·Ownership limits prevent beneficial ownership exceeding 4.99% or 9.99% post-exercise.
• ·Offering pursuant to S-1 Registration Statement (No. 333-294887) effective April 23, 2026.

27-04-2026

uniQure N.V. filed its DEF 14A definitive proxy statement on April 27, 2026, for the 2026 Annual General Meeting on June 10, 2026, at 9:00 a.m. CEST in Amsterdam, covering adoption of 2025 Dutch statutory annual accounts, discharge of Board liability, and reappointments of non-executive directors Madhavan Balachandran, Jack Kaye, and Leonard Post, Ph.D. The agenda also includes authorizations for share issuances and repurchases, appointment of KPMG Accountants N.V. as 2026 external auditors, advisory votes on executive compensation and frequency, and amendments to the 2014 Share Incentive Plan (increasing available shares) and Articles of Association.

• ·Record date: close of business CEST on May 13, 2026.
• ·Voting deadline: 9:59 p.m. CEST on June 9, 2026; attendance notice by 12:00 p.m. CEST on June 9, 2026 via investors@uniQure.com.
• ·Meeting location: Paasheuvelweg 25a, 1105 BP Amsterdam, the Netherlands.

27-04-2026

U.S. Energy Corp. (NASDAQ: USEG) executed a five-year, 100% take-or-pay helium offtake agreement with an unnamed investment-grade global industrial gas company for up to 1.2 MMCF per month (14.4 MMCF annually) from its Big Sky Carbon Hub at a fixed $285/MCF plant-gate price, with annual CPI-linked escalation starting March 1, 2028. The deal fully contracts Phase 1 helium volumes, supporting commercial operations targeted for Q1 2027 and de-risking the project alongside a recently expanded senior secured credit facility. No declines or flat metrics reported; the agreement positions helium as the initial contracted revenue stream in a multi-revenue platform including carbon management.

• ·Five-year initial term with year-three price redetermination option
• ·Phase 1 commercial operations targeted for Q1 2027; Phase 2 expected 2029 with 2-3x processing capacity
• ·Counterparty assumes all transportation, processing, and downstream costs
• ·EPA MRV plan approvals anticipated summer 2026
• ·Expanded senior secured credit facility closed April 20, 2026

27-04-2026

Miami International Holdings, Inc. (MIAX) filed a definitive proxy statement (DEF 14A) on April 27, 2026, for its 2026 Annual Meeting of Stockholders on June 16, 2026, at 8:00 a.m. ET via live webinar with no physical location. Shareholders will vote on electing 15 directors to serve until the 2027 annual meeting, approving on a non-binding advisory basis the compensation of named executive officers and the frequency of future say-on-pay votes (every 1, 2, or 3 years), and ratifying KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026.

• ·Record date for voting eligibility: April 20, 2026
• ·Virtual meeting access: www.virtualshareholdermeeting.com/MIAX2026 with 16-digit control number
• ·Proxy materials and Form 10-K for year ended December 31, 2025 available at http://ir.miaxglobal.com under 'SEC Filings'

27-04-2026

Suja Life, Inc. filed an S-1/A registration statement amendment on April 27, 2026, disclosing risks related to becoming a public company, including potential material weaknesses in internal controls, significant compliance costs under Sarbanes-Oxley Section 404, and strains on management resources. As an emerging growth company, the firm plans to utilize JOBS Act exemptions, such as delayed auditor attestation on internal controls and reduced executive compensation disclosures, potentially lasting until 2031 unless annual gross revenues exceed $1.235 billion or more than $1.0 billion in non-convertible debt is issued. These factors could lead to less attractive stock, volatile pricing, higher expenses, and diversion of management focus from business growth.

• ·Emerging growth company status eligible for up to five years after first sale of Class A common stock, with fifth anniversary in 2031.
• ·Exemptions include no auditor attestation under Section 404 until later of year after first annual report or no longer EGC.
• ·Subject to ongoing quarterly disclosures of changes in internal controls and procedures.

27-04-2026

Solstice Advanced Materials Inc. announced a quarterly dividend of $0.075 per share on April 27, 2026, payable on June 10, 2026, to shareholders of record as of the close of business on May 27, 2026. The press release detailing the dividend is filed as Exhibit 99.1.

• ·Filing date: April 27, 2026; Date of earliest event: April 24, 2026
• ·Common stock: par value $0.01 per share, trading symbol SOLS on Nasdaq
• ·Principal executive offices: 115 Tabor Road, Morris Plains, New Jersey 07950

27-04-2026

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced the appointment of Daniel B. Gilmer, Ph.D., a biopharmaceutical commercial executive and current Senior Director at Pfizer Inc., to its Board of Directors, effective April 24, 2026. Dr. Gilmer brings extensive experience in commercial launches, including leading the U.S. rollout of PAXLOVID and co-inventing Exebacase (CF-301/PlySs2), a bacteriophage lysin that received FDA Fast Track and Breakthrough Therapy designations. The appointment aims to bolster Armata's efforts to commercialize its pathogen-specific bacteriophage therapeutics for antibiotic-resistant infections.

• ·Dr. Gilmer joined Pfizer in May 2019; led U.S. PAXLOVID launch after FDA New Drug Approval.
• ·Previously at Pfizer: Antiviral and Diagnostics Business (Apr 2022-Feb 2025), Inflammation & Immunology (Apr 2021-Apr 2022).
• ·Ph.D. in Microbiology from Rockefeller University; B.S. from Howard University.
• ·Serves on Rockefeller University Board of Trustees Educational Affairs Committee and Ford Center Incubator selection committee.
• ·Member of New York Academy of Sciences and term member at Council on Foreign Relations.

27-04-2026

Hemab ApS reported increasing net losses of $48,707 thousand in 2024 and $63,913 thousand in 2025, driven by a 44% YoY rise in R&D expenses to $59,632 thousand and higher cash burn from operations at $61,475 thousand. However, the company raised $156,421 thousand net from Series C convertible preference shares in 2025, boosting cash and equivalents to $87,974 thousand, marketable securities to $97,511 thousand, and total assets to $194,783 thousand. This S-1/A filing supports an IPO registration, highlighting clinical-stage assets like sutacimig (HMB-001) and HMB-002.

• ·Ordinary shares outstanding remained flat at 946,000 throughout 2024 and 2025.
• ·Stockholders’ deficit widened to $(176,635) thousand as of December 31, 2025 from $(115,273) thousand.
• ·Series C shares issued: 512,991 shares with liquidation preference of $156,898 thousand.

27-04-2026

Alphageo (India) Limited has initiated the second 'Saksham Niveshak' 100 Days Campaign from 1st April 2026 to 9th July 2026 to raise awareness among shareholders about unclaimed dividends and shares at risk of transfer to IEPF. The company has communicated via emails and letters, urging updates to KYC, nomination, and bank details using forms ISR-1, ISR-2, and SH-13 submitted to RTA KFin Technologies Limited. Details are available on the company website and RTA portal.

• ·Campaign deadline for submissions: July 9, 2026
• ·IEPF details: https://www.alphageoindia.com/IEPF.htm
• ·Unclaimed Dividends details: https://www.alphageoindia.com/Unclaimed%20Dividends.htm
• ·RTA submission options: Hard copy to Selenium Tower B, Plot Nos. 31 & 32, Financial District, Nanakramguda, Serilingampally Mandal, Hyderabad - 500032; email einward.ris@kfintech.com; or https://ris.kfintech.com
• ·Forms download: https://ris.kfintech.com/clientservices/isc/isrforms.aspx
• ·Company notice: https://www.alphageoindia.com/SAKSHAM_NIVESHAK 2026.htm